Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Partial seizures, also known as focal seizures, are characterized by abnormal electrical activity originating in a specific region of the brain, leading to motor, sensory, or cognitive disturbances. According to Yue Hu et al., 2024, nearly 50 million people worldwide live with epilepsy, and effective treatment can control seizures in up to 70% of patients. According to the partial seizure pipeline analysis by Expert Market Research, the drug pipeline is expanding with a strong focus on novel antiepileptic therapies, precision medicine, and improved safety profiles. The rising disease burden, unmet needs in drug-resistant cases, and ongoing R&D investments are expected to support steady growth in the years to come.
-
Major companies involved in the partial seizure pipeline analysis include Praxis Precision Medicines, Rapport Therapeutics Inc., and others.
-
Leading drugs currently in the pipeline include PRAX-628, RAP-219, SPN-817, and others.
-
The robust pipeline expansion is driven by targeted mechanisms, next-generation antiepileptic molecules, and rising clinical activity focused on improved seizure control, tolerability, and addressing drug-resistant patient populations.
Report Coverage
The Partial Seizure Pipeline Analysis Report by Expert Market Research gives comprehensive insights into partial seizure therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for partial seizure. The partial seizure report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The partial seizure pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with partial seizure treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to partial seizure.
Read more about this report - Request a Free Sample
Partial Seizure Pipeline Outlook
Partial seizure, also known as a focal seizure, originates in a specific region of the brain due to abnormal electrical activity. It occurs when localized neuronal circuits become hyperexcitable, often triggered by structural brain changes, infections, trauma, tumors, or genetic factors. Symptoms vary based on the affected brain area and may include motor, sensory, autonomic, or cognitive disturbances.
Partial seizure treatment focuses on seizure control using anti-seizure medications, surgical intervention, or neuromodulation therapies. Management aims to reduce seizure frequency, prevent progression, and improve patient quality of life. In April 2024, Neurona Therapeutics reported positive Phase 1/2 clinical data for NRTX-1001, a regenerative cell therapy showing substantial seizure reduction and favorable tolerability in adults with drug-resistant focal epilepsy.
Partial Seizure Epidemiology
The partial seizure drug pipeline analysis is driven by epidemiological trends and evolving treatment demand. According to Yue Hu et al., epilepsy affects approximately 50 million people globally, highlighting the sustained need for effective therapies targeting focal seizures. As per Susanne Schubert-Bast et al., the annual incidence of focal onset seizures in children aged 0-4 years ranges from 25.1 per 100,000 in the United Kingdom to 111.8 per 100,000 in the United States. Period prevalence varies between 0.15% in Canada and 0.61% in the United States. Overall, these incidence and prevalence patterns reinforce continued research investment and pipeline development for partial seizure management.
Partial Seizure – Pipeline Therapeutic Assessment
This section of the report covers the analysis of partial seizure drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The partial seizure pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
Partial Seizure Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 42%, covers a major share of the total partial seizure clinical trials. It is followed by phase III at 35%. Phase I and phase IV each hold approximately 12% of the total partial seizure clinical trial landscape. The strong presence of advanced phases indicates robust development, supporting future market growth, enhanced treatment options, and potential acceleration of drug approvals in the partial seizure segment.
Partial Seizure Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the partial seizure pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The partial seizure report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for partial seizure. In the partial seizure drug pipeline, AMPA receptor modulators are emerging as promising therapies. For example, RAP-219 is a small molecule, a TARPγ8-specific AMPA receptor negative allosteric modulator, that is under Phase 2a investigation for drug-resistant focal onset seizures. It selectively targets receptors in seizure-prone brain regions, demonstrating significant reductions in seizure frequency and promising tolerability, supporting its advancement into Phase 3 clinical trials.
Partial Seizure Clinical Trials – Key Players
The EMR report for the partial seizure pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed partial seizure therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in partial seizure clinical trials:
- Praxis Precision Medicines
- Rapport Therapeutics Inc.
- SK Life Science, Inc.
- Xenon Pharmaceuticals Inc.
- Supernus Pharmaceuticals, Inc.
- Jazz Pharmaceuticals
- Ono Pharmaceutical Co. Ltd.
- Eisai Inc.
- Biohaven Therapeutics Ltd.
- Neurona Therapeutics
Partial Seizure – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for partial seizures. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of partial seizure drug candidates.
Drug: PRAX-628
PRAX-628 is a next-generation, functionally selective small-molecule sodium-channel modulator being developed as a once-daily oral treatment for adults with focal seizures. The drug is selectively targeting hyperexcitable NaV channels in the brain, aiming to suppress seizure activity while preserving normal neuronal signaling. The ongoing POWER1 study, sponsored by Praxis Precision Medicines, is a double-blind, randomized Phase 2/3 trial evaluating the efficacy and safety of PRAX-628 in adults receiving one to three concomitant anti-seizure medications. The study is examining seizure reduction and tolerability, with primary completion expected in November 2025 and overall study completion anticipated in December 2025.
Drug: RAP-219
RAP-219 is being evaluated in a Phase 2, open-label, long-term study for adults with refractory focal onset seizures. Sponsored by Rapport Therapeutics Inc., the study is examining long-term safety, tolerability, pharmacokinetics, pharmacodynamics, and sustained antiseizure effectiveness. RAP-219 is a first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator, selectively targeting seizure-related brain regions such as the hippocampus and neocortex. This precision-based mechanism aims to reduce seizures while minimizing adverse effects. The study is expected to begin in November 2025, with completion anticipated by February 2028.
Drug: SPN-817
SPN-817 is progressing as a novel anticonvulsant for focal onset seizures, sponsored by Supernus Pharmaceuticals, Inc. The ongoing Phase 2b open-label extension study is evaluating the long-term safety, tolerability, and efficacy of SPN-817 in adults previously completing double-blind trials. The study is examining seizure control over one year. SPN-817 is a synthetic form of huperzine A, working through potent acetylcholinesterase inhibition to modulate central nervous system activity. The drug is being administered via an extended-release oral route. Study completion is estimated for December 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Partial Seizure Pipeline Insight Report
- Which companies/institutions are leading the partial seizure drug development?
- Which company is leading the partial seizure pipeline development activities?
- What is the current partial seizure commercial assessment?
- What are the opportunities and challenges present in the partial seizure pipeline landscape?
- What is the efficacy and safety profile of partial seizure pipeline drugs?
- Which company is conducting major trials for partial seizure drugs?
- Which companies/institutions are involved in partial seizure collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in partial seizure?
Reasons To Buy This Report
The Partial Seizure Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for partial seizure. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into partial seizure collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Seizures Drug Pipeline Analysis Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share